Flotrac/Vigileo监测下输液在高龄患者腹腔镜下膀胱癌根治术中的应用

宋振东; 闻绍云; 李欣

doi:10.16766/j.cnki.issn.1674-4152.001865

Flotrac/Vigileo监测下输液在高龄患者腹腔镜下膀胱癌根治术中的应用

doi: 10.16766/j.cnki.issn.1674-4152.001865

1.
台州市中心医院麻醉科，浙江台州 318000
2.
台州市中心医院神经内科，浙江台州 318000
3.
台州市中心医院泌尿外科，浙江台州 318000

基金项目:

浙江省公益技术应用社会发展项目 LGF19H050004

详细信息

通讯作者:
闻绍云, E-mail: wensy@tzzxyy.com

中图分类号: R615 R737.14
计量
- 文章访问数: 213
- HTML全文浏览量: 68
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2020-10-21
- 网络出版日期: 2022-02-16

Application of fluid infusion under Flotrac/Vigileo monitoring in laparoscopic radical cystectomy for bladder cancer in elderly patients

1.
Department of Anesthesiology, Taizhou Central Hospital, Taizhou, Zhejiang 318000, China

摘要

摘要: 目的探讨Flotrac/Vigileo监测下输液对腹腔镜膀胱癌根治术患者术后恢复和炎症反应的影响。方法选择台州市中心医院2019年1月—2019年12月腹腔镜膀胱癌根治术患者160例，根据随机数字法分为A组和B组，每组80例。A组给予421法液体输注，B组根据Flotrac/Vigileo监测结果进行液体输注。分别采集患者术前、术后1 d、术后3 d和术后7 d外周静脉血，分离血清，采用双抗夹心酶联免疫吸附试验测定血清肿瘤坏死因子-α(TNF-α)、白细胞介素-2(IL-2)、IL-6水平。结果 2组麻醉时间、手术时间、术后苏醒时间、液体总量、出血量和尿量、血流动力学、并发症、住院时间、膀胱容量、最大尿流率、膀胱内压差异无统计学意义(均P > 0.05)。B组胶体液量[(1 291.45±224.83)mL]高于A组(P < 0.05)，晶体液量[(992.13±234.15)mL]低于A组(P < 0.05)。B组肛门排气时间[(61.35±14.16)h]、首次下床时间[(6.34±1.42)h]、恢复进食时间[(3.51±1.07)h]均小于A组(均P < 0.05)。与术前比较，2组术后1 d和术后3 d血清TNF-α、IL-6水平升高(均P < 0.05)，IL-2水平降低(P < 0.05)；B组术后1 d和术后3 d血清TNF-α、IL-6水平高于A组(均P < 0.05)，IL-2水平低于A组(P < 0.05)。结论 Flotrac/Vigileo监测下输液可促进腹腔镜膀胱癌根治术患者术后恢复，抑制围手术期炎症反应。
- Flotrac/Vigileo监护系统 /
- 输液管理 /
- 腹腔镜膀胱癌根治术 /
- 炎症
Abstract: Objective This study aimed to investigate the effects of infusion under Flotrac/Vigileo monitoring on postoperative recovery and inflammatory response in patients undergoing laparoscopic radical cystectomy for bladder cancer. Methods A total of 160 patients undergoing laparoscopic radical cystectomy for bladder cancer in Taizhou Central Hospital from January 2019 to December 2019 were selected and divided into group A and group B by the random number method, with 80 patients in each group. Group A was given liquid infusion based on "4/2/1" rule for Ⅳ, and group B was given liquid infusion according to Flotrac/Vigileo monitoring results. Peripheral venous blood was collected before surgery, 1 day after surgery, 3 days after surgery and 7 days after surgery. Serum samples were separated. Serum levels of tumour necrosis factor-α (TNF-α), interleukin-2 (IL-2) and IL-6 were determined by double-antibody ELISA. Results No significant differences in anaesthesia time, operation duration, postoperative recovering time, total fluid volume, blood loss and urine volume, haemodynamics, complications, length of hospital stay, bladder volume, maximum urine flow rate and bladder pressure were found between the two groups (all P > 0.05). The amount of colloid Ⅳ solution in group B [(1 291.45±224.83) mL] was higher than that in group A (P < 0.05), and the amount of crystalloid Ⅳ solutions in group B [(992.13±234.15) mL] was lower than that in group A (P < 0.05). The anal exhaust time of group B [(61.35±14.16) h], time to post-operative ambulation [(6.34±1.42) h] and time of resuming feeding [(3.51±1.07) h] were all shorter than those of group A (all P < 0.05). Compared with preoperation, the serum levels of TNF-α and IL-6 increased and IL-2 decreased in the two groups at 1 and 3 days after operation (P < 0.05). The serum levels of TNF-α and IL-6 in group B were higher than those in group A, while the serum level of IL-2 was lower than that in group A (P < 0.05). Conclusion Infusion under Flotrac/Vigileo monitoring can promote postoperative recovery and inhibit perioperative inflammatory response in patients undergoing radical laparoscopic radical bladder cancer surgery.
- Flotrac/Vigileo system monitoring /
- Infusion management /
- Laparoscopic radical bladder cystectomy /
- Inflammation

HTML全文

表 1 2组膀胱癌根治术患者一般资料比较(例)

组别	例数	年龄(x±s，岁)	性别(男/女)	ASA(Ⅰ/Ⅱ/Ⅲ)	体重(x±s，kg，)	身高(x±s，cm)	糖尿病	高血压	冠心病
A组	80	54.13±9.46	53/27	22/50/8	68.24±14.16	165.37±18.42	10	18	7
B组	80	53.76±9.24	54/26	20/51/9	68.53±13.67	164.53±17.59	9	19	6
统计量		0.250^a	0.028^b	0.404^c	0.132^a	0.358^a	0.060^b	0.035^b	0.084^b
P值		0.803	0.867	0.666	0.895	0.721	0.807	0.851	0.772
注：^a为t值，^b为χ²值，^c为Z值。

下载: 导出CSV

表 2 2组膀胱癌根治术患者手术情况比较(x ±s，min)

组别	例数	麻醉时间	手术时间	术后苏醒时间
A组	80	513.20±92.13	345.16±84.32	31.02±8.57
B组	80	491.25±97.52	337.42±82.13	28.79±7.64
t值		1.463	0.588	1.737
P值		0.145	0.557	0.084

下载: 导出CSV

表 3 2组膀胱癌根治术患者液体出入量比较(x ±s，mL)

组别	例数	液体总量	胶体液量	晶体液量	出血量	尿量
A组	80	3 864.52±532.10	992.13±234.15	2 865.19±264.32	185.46±61.37	647.53±62.35
B组	80	3 792.30±547.58	1 291.45±224.83	2 501.13±259.26	179.54±63.52	654.31±59.48
t值		0.846	8.247	8.795	0.600	0.704
P值		0.399	< 0.001	< 0.001	0.549	0.482

下载: 导出CSV

表 4 2组膀胱癌根治术患者血流动力学比较(x ±s)

组别	例数	项目	T1	T2	T3	T4	T5
A组	80	SBP(mm Hg)	112.36±13.41	96.53±12.62^a	108.52±13.04	104.35±12.81	109.87±11.68
		DBP(mm Hg)	72.35±9.42	64.17±10.24^a	68.19±11.13	68.48±11.85	69.14±11.37
		HR(次/min)	76.35±8.64	73.24±9.37	72.13±9.06	72.58±10.02	73.69±9.62
B组	80	SBP(mm Hg)	113.24±14.02	97.14±13.25^a	107.34±12.76	105.06±11.98	111.13±10.32
		DBP(mm Hg)	73.02±9.84	65.27±10.85^a	68.82±11.25	69.42±12.03	70.52±11.59
		HR(次/min)	76.94±8.57	73.82±9.45	73.02±9.47	73.86±9.51	74.38±9.37
注：与T1比较，^aP < 0.05；1 mm Hg=0.133 kPa。

下载: 导出CSV

表 5 2组膀胱癌根治术患者术后恢复情况(x ±s)

组别	例数	肛门排气时间(h)	首次下床时间(h)	恢复进食时间(h)	并发症(例)	住院时间(d)
A组	80	69.83±15.42	7.02±1.51	4.15±1.14	8	19.86±6.52
B组	80	61.35±14.16	6.34±1.42	3.51±1.07	7	18.92±6.47
统计量		3.623^a	2.934^a	3.661^a	0.074^b	0.915^a
P值		< 0.001	0.004	< 0.001	0.786	0.360
注：^a为t值，^b为χ²值。

下载: 导出CSV

表 6 2组膀胱癌患者根治术后膀胱功能比较(x ±s)

组别	例数	膀胱容量(mL)	最大尿流率(mg/s)	膀胱内压(cm H₂O)
A组	80	351.24±41.23	15.32±2.14	18.79±2.34
B组	80	348.56±39.51	15.46±2.23	18.87±2.41
t值		0.420	0.405	0.213
P值		0.675	0.686	0.832
注：1 cm H₂O=0.098 kPa。

下载: 导出CSV

表 7 2组各时间点血清TNF-α、IL-2、IL-6水平比较(x ±s，ng/L)

组别	例数	项目	术前	术后1 d	术后3 d	术后7 d
A组	80	TNF-α	21.03±4.12	82.13±15.64^a	71.25±13.62^a	22.14±5.02
		IL-2	4.31±0.53	3.12±0.43^a	3.76±0.51^a	4.22±0.64
		IL-6	12.51±5.02	68.73±6.21^a	57.32±6.02^a	14.13±6.14
B组	80	TNF-α	20.57±4.25	71.15±16.24^ab	58.38±12.46^ab	21.37±4.86
		IL-2	4.28±0.49	2.35±0.37^ab	3.12±0.46^ab	4.16±0.62
		IL-6	12.62±4.86	60.57±6.18^ab	48.35±5.46^ab	13.41±6.08
注：组内比较, 与术前比较，^aP < 0.05；2组之间比较, 与A组比较，^bP < 0.05。

下载: 导出CSV

参考文献(21)

[1]	SUBIRA-RIOS D, HERRANZ-AMO F, RENEDO-VILLAR T, et al. Influence of laparoscopic access in cancer-specific mortality of patients with pTa-2pN0R0 bladder cancer treated with radical cistectomy[J]. Actas Urol Esp, 2019, 43(5): 241-247. doi: 10.1016/j.acuro.2019.01.001
[2]	MATSUMOTO K, TABATA K I, HIRAYAMA T, et al. Robot-assisted laparoscopic radical cystectomy is a safe and effective procedure for patients with bladder cancer compared to laparoscopic and open surgery: Perioperative outcomes of a single-center experience[J]. Asian J Surg, 2019, 42(1): 189-196. doi: 10.1016/j.asjsur.2017.11.002
[3]	杨朝裕, 邓超雄, 林志艺, 等. 腹腔镜膀胱癌根治术的疗效分析及其对患者血清细胞因子水平、应激反应的影响[J]. 中国医药科学, 2019, 9(22): 27-30. doi: 10.3969/j.issn.2095-0616.2019.22.010
[4]	文新灵, 景桂霞, 何平, 等. 每搏量变异度指导老年腹腔镜胃癌根治术容量管理的临床研究[J]. 西安交通大学学报(医学版), 2016, 37(6): 851-856. https://www.cnki.com.cn/Article/CJFDTOTAL-XAYX201606016.htm
[5]	KUSAKA Y, OHCHI F, MINAMI T. Evaluation of the fourth-generation Flotrac/Vigileo system in comparison with the intermittent bolus thermodilution method in patients undergoing cardiac surgery[J]. J Cardiothorac Vasc Anesth, 2019, 33(4): 953-960. doi: 10.1053/j.jvca.2018.06.017
[6]	MAEDA T, HAMAGUCHI E, KUBO N, et al. The accuracy and trending ability of cardiac index measured by the fourth-generation FloTrac/Vigileo system^TM and the Fick method in cardiac surgery patients[J]. J Clin Monit Comput, 2019, 33(5): 767-776. doi: 10.1007/s10877-018-0217-1
[7]	李志文, 赵壮, 潘树, 等. 小剂量去甲肾上腺素持续泵入联合限制性输液策略在腹腔镜胃癌根治术中的应用[J]. 中国老年学杂志, 2016, 36(22): 5624-5626. doi: 10.3969/j.issn.1005-9202.2016.22.059
[8]	白丽红, 张树波, 刘铁军. 目标导向液体治疗对老年患者结肠癌手术肠道屏障的影响[J]. 实用医学杂志, 2016, 32(10): 1612-1615. doi: 10.3969/j.issn.1006-5725.2016.10.018
[9]	MAEDA T, HATTORI K, SUMIYOSHI M, et al. Accuracy and trending ability of the fourth-generation FloTrac/Vigileo system^TM in patients undergoing abdominal aortic aneurysm surgery[J]. J Anesth, 2018, 32(3): 387-393. doi: 10.1007/s00540-018-2491-y
[10]	HATTORI K, MAEDA T, MASUBUCHI T, et al. accuracy and trending ability of the fourth-generation Flotrac/Vigileo system in patients with low cardiac index[J]. J Cardiothorac Vasc Anesth, 2017, 31(1): 99-104. doi: 10.1053/j.jvca.2016.06.016
[11]	SOHDA M, KURIYAMA K, KUMAKURA Y, et al. Evaluation of surgical procedures that affect the hemodynamics using the flotrac system in esophageal cancer patients[J]. In Vivo, 2019, 33(4): 1221-1226. doi: 10.21873/invivo.11593
[12]	HARA M, HIRAKI T. Circulatory Management using FloTrac/Vigileo and transesophageal echocardiography for mesenteric traction syndrome during colectomy in a patient with hypertrophic cardiomyopathy[J]. J Cardiothorac Vasc Anesth, 2020, 34(4): 1015-1018. doi: 10.1053/j.jvca.2019.12.023
[13]	HAMED M A, GODA A S, ELDEIN R M S. Comparison of goal-directed hemodynamic optimization using pulmonary artery catheter and autocalibrated arterial pressure waveform analysis Vigileo-FloTrac^TM system in on-pump coronary artery bypass graft surgery: a randomized controlled studya[J]. Anesth Essays Res, 2018, 12(2): 517-521. doi: 10.4103/aer.AER_58_18
[14]	宋哲, 周治军, 徐康, 等. 腹腔镜下根治性膀胱切除术治疗膀胱癌的疗效及对患者血清IL-6及IFN-γ水平的影响[J]. 现代生物医学进展, 2017, 17(21): 4100-4103, 4146. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201721026.htm
[15]	宫升, 张桂铭, 朱崇晖, 等. IL-6对根治性膀胱切除术患者预后的影响[J]. 临床泌尿外科杂志, 2019, 34(1): 48-51. https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW201901012.htm
[16]	MIYAKE M, HORI S, OHNISHI S, et al. Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer[J]. Cancer Sci, 2019, 110(10): 3315-3327. doi: 10.1111/cas.14158
[17]	陈炜佳, 张树波, 杨超杰, 等. 联合麻醉下目标导向液体治疗对炎症细胞因子的影响[J]. 实用医学杂志, 2018, 34(4): 604-608. doi: 10.3969/j.issn.1006-5725.2018.04.020
[18]	谷洁, 高志峰, 王晓宇, 等. 基于不同目标的目标导向液体治疗对高危腹部手术患者围术期血管内皮多糖包被的影响: 前瞻性随机对照研究[J]. 中华麻醉学杂志, 2018, 38(6): 707-711. doi: 10.3760/cma.j.issn.0254-1416.2018.06.018
[19]	SUSHAMA S, DIXIT N, GAUTAM R K, et al. Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-α) in vitiligo-New insight into pathogenesis of disease[J]. J Cosmet Dermatol, 2019, 18(1): 337-341. doi: 10.1111/jocd.12517
[20]	WU C T, LIN W Y, CHEN W C, et al. Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling[J]. Ann Surg Oncol, 2018, 25(12): 3518-3526. doi: 10.1245/s10434-018-6706-0
[21]	GONG W, HOFFMANN JM, STOCK S, et al. Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells[J]. Cancer Immunol Immunother, 2019, 68(7): 1195-1209. doi: 10.1007/s00262-019-02354-4